{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:54:53Z","timestamp":1791179693570,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.advms.2014.12.002","type":"journal-article","created":{"date-parts":[[2014,12,25]],"date-time":"2014-12-25T05:00:50Z","timestamp":1419483650000},"page":"83-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["New therapeutic options for advanced non-resectable malignant melanoma"],"prefix":"10.1016","volume":"60","author":[{"given":"Simone","family":"Stadler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasia","family":"Weina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Utikal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 6","key":"10.1016\/j.advms.2014.12.002_bib0005","first-page":"1","article-title":"Malignant melanoma S3-guideline \u201cdiagnosis, therapy and follow-up of melanoma\u201d","volume":"11","author":"Pflugfelder","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.advms.2014.12.002_bib0010","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.advms.2014.12.002_bib0015","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","article-title":"Phase II trial (BREAK-2) of the braf inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma","volume":"31","author":"Ascierto","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5s","key":"10.1016\/j.advms.2014.12.002_bib0020","article-title":"Phase II study of vemurafenib in patients with locally advanced, unresectable stage IIIc or metastatic melanoma and activating exon 15 BRAF mutations other than V600E","volume":"32","author":"Hallmeyer","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-3083.2012.04546.x","article-title":"Cutaneous side effects of inhibitors of the RAS\/RAF\/MEK\/ERK signalling pathway and their management","volume":"27","author":"Manousaridis","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5s","key":"10.1016\/j.advms.2014.12.002_bib0030","article-title":"Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763)","volume":"32","author":"Ascierto","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0035","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0040","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/annonc\/mdt587","article-title":"Differential influence of vemurafenib and dabrafenib on patients\u2019 lymphocytes despite similar clinical efficacy in melanoma","volume":"25","author":"Schilling","year":"2014","journal-title":"Ann Oncol"},{"issue":"28","key":"10.1016\/j.advms.2014.12.002_bib0045","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1097\/MD.0000000000000161","article-title":"Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report","volume":"93","author":"Orouji","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.advms.2014.12.002_bib0050","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0055","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","article-title":"Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition","volume":"30","author":"Zimmer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"S4","key":"10.1016\/j.advms.2014.12.002_bib0065","article-title":"A phase 1, does escalation study of paclitaxel with GSK1120212 (Trametinib) for the treatment of advanced melanoma","volume":"25","author":"Coupe","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0070","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(13)70237-7","article-title":"Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study","volume":"14","author":"Robert","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0075","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1158\/1078-0432.CCR-13-2349","article-title":"Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient \u2013 letter","volume":"20","author":"Bernhardt","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.advms.2014.12.002_bib0080","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ejca.2013.09.014","article-title":"Dermatology Cooperative Oncology Group (DeCOG). Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients","volume":"50","author":"Goldinger","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.advms.2014.12.002_bib0085","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.advms.2014.12.002_bib0090","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0095","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/nm.2941","article-title":"Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma","volume":"18","author":"Kwong","year":"2012","journal-title":"Nat Med"},{"issue":"5s","key":"10.1016\/j.advms.2014.12.002_bib0100","article-title":"A phase 1b\/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity","volume":"32","author":"Sosman","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0105","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2012.44.7888","article-title":"Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma","volume":"31","author":"Trunzer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature11814","article-title":"Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance","volume":"494","author":"Das Thakur","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.advms.2014.12.002_bib0115","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.advms.2014.12.002_bib0120","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.advms.2014.12.002_bib0125","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.9029","article-title":"Preliminary results from a phase Ib\/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1\/2 inhibitor MEK162 in BRAFV600-dependent advanced solid tumors","volume":"31","author":"Kefford","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5s","key":"10.1016\/j.advms.2014.12.002_bib0130","article-title":"Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM)","volume":"32","author":"Flaherty","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0135","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1470-2045(14)70301-8","article-title":"Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study","volume":"15","author":"Ribas","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0140","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.advms.2014.12.002_bib0145","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.advms.2014.12.002_bib0150","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","author":"Robert C1","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.advms.2014.12.002_bib0155","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.advms.2014.12.002_bib0160","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0165","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0170","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1535-7163.MCT-09-0459","article-title":"Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates","volume":"8","author":"Woodman","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.advms.2014.12.002_bib0175","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/cncr.25766","article-title":"A phase 2 trial of dasatinib in advanced melanoma","volume":"117","author":"Kluger","year":"2011","journal-title":"Cancer"},{"issue":"5s","key":"10.1016\/j.advms.2014.12.002_bib0180","article-title":"Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification","volume":"32","author":"Lebbe","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0185","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"5s","key":"10.1016\/j.advms.2014.12.002_bib0190","article-title":"Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups","volume":"32","author":"Zimmer","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0195","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1002\/cncr.28282","article-title":"Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience","volume":"119","author":"Luke","year":"2013","journal-title":"Cancer"},{"issue":"5s","key":"10.1016\/j.advms.2014.12.002_bib0200","article-title":"Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): the GEM-1 trial","volume":"32","author":"Piulats Rodriguez","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0205","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1634\/theoncologist.2012-0464","article-title":"Ipilimumab for patients with advanced mucosal melanoma","volume":"18","author":"Postow","year":"2013","journal-title":"Oncologist"},{"issue":"5s","key":"10.1016\/j.advms.2014.12.002_bib0210","article-title":"Efficacy of two ipilimumab (IPI) doses (10 vs. 3mg\/kg) in Alberta, Canada, tertiary cancer centers","volume":"32","author":"Lee-Ying","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5s","key":"10.1016\/j.advms.2014.12.002_bib0215","article-title":"Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial","volume":"32","author":"Eggermont","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0220","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.advms.2014.12.002_bib0225","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.advms.2014.12.002_bib0230","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.advms.2014.12.002_bib0235","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"5s","key":"10.1016\/j.advms.2014.12.002_bib0240","article-title":"Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)","volume":"32","author":"Ribas","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5s","key":"10.1016\/j.advms.2014.12.002_bib0245","article-title":"Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial","volume":"32","author":"Hodi","year":"2014","journal-title":"J Clin Oncol"},{"issue":"S4","key":"10.1016\/j.advms.2014.12.002_bib0250","article-title":"A phase 3 randomized, open-label study of nivolumab (anti-PD-1, BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma and prior anti-CTLA-4 therapy","volume":"25","author":"Weber","year":"2014","journal-title":"Ann Oncol"},{"issue":"5s","key":"10.1016\/j.advms.2014.12.002_bib0255","article-title":"Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)","volume":"32","author":"Sznol","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2014.12.002_bib0260","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJMc1302338","article-title":"Hepatotoxicity with combination of vemurafenib and ipilimumab","volume":"368","author":"Ribas","year":"2013","journal-title":"N Engl J Med"},{"issue":"5s","key":"10.1016\/j.advms.2014.12.002_bib0265","article-title":"A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIB\/C\/IV melanoma","volume":"32","author":"Kudchadkar","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S189611261400100X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S189611261400100X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T11:22:50Z","timestamp":1598613770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S189611261400100X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S189611261400100X"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2014.12.002","relation":{},"ISSN":["1896-1126"],"issn-type":[{"value":"1896-1126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New therapeutic options for advanced non-resectable malignant melanoma","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2014.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Medical University of Bialystok. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}